News Summary: Merck settles cholesterol drug suits

Published



SUIT SETTLEMENT: Drugmaker Merck agreed to pay $688 million to settle two investor lawsuits over a long delay in releasing results of a study meant to show its blockbuster cholesterol drugs reduced plaque buildup in arteries. But it found that Merck’s Zetia and Vytorin were no better than a cheap generic pill.

MERCK RESPONSE: Merck admits no wrongdoing and said it was in its best interest to end the suits.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.